1
Return

A Phase 1 trial of iron metabolism-targeting oral gallium maltolate in recurrent and refractory glioblastoma

delete2026-06-08
delete0
delete
OA
AI
J
Jennifer M Connelly *
C
Casey J Zoss
A
Aniko Szabo
S
Shama P Mirza
F
Frederick Adom
L
Lawrence R Bernstein
M
Mona M Al-Gizawiy
K
Kathleen M Schmainda
C
Christopher R Chitambar *
DOI：10.1093/noajnl/vdag154delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Gallium maltolate is an oral compound that disrupts iron-dependent glioblastoma (GBM) growth and prolongs survival in animal models. This Phase 1 trial of oral gallium maltolate in patients with recurrent GBM was conducted to assess toxicity, determine a recommended Phase 2 dose (RP2D), and seek signals of tumor response.

Journal

N
Neuro-Oncology Advances
IF:
4.1
Papers:
1.5K
Citations:
3.2K

Organization

G
gallixa llc
Scholars:
2
Papers: 1
Citations: 0
M
medical college of wisconsin
Scholars:
1.7W
Papers: 1.2W
Citations: 9
U
university of wisconsin
Scholars:
1.2K
Papers: 565
Citations: 0
Cited Papers

Cited Papers

Citing Papers

Citing Papers